NYSE:CHE Chemed (CHE) Stock Price, News & Analysis $600.46 +14.34 (+2.45%) Closing price 02/28/2025 03:59 PM EasternExtended Trading$599.98 -0.48 (-0.08%) As of 02/28/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Chemed Stock (NYSE:CHE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Chemed alerts:Sign Up Key Stats Today's Range$583.19▼$603.4350-Day Range$517.44▼$600.4652-Week Range$512.12▼$654.62Volume141,070 shsAverage Volume96,197 shsMarket Capitalization$9.04 billionP/E Ratio30.34Dividend Yield0.33%Price Target$633.00Consensus RatingBuy Company OverviewChemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.Read More… Chemed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreCHE MarketRank™: Chemed scored higher than 87% of companies evaluated by MarketBeat, and ranked 152nd out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingChemed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageChemed has received no research coverage in the past 90 days.Read more about Chemed's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth8.73% Earnings GrowthEarnings for Chemed are expected to grow by 8.73% in the coming year, from $21.43 to $23.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemed is 30.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemed is 30.34, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.04.Price to Earnings Growth RatioChemed has a PEG Ratio of 2.15. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioChemed has a P/B Ratio of 8.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Chemed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.13% of the float of Chemed has been sold short.Short Interest Ratio / Days to CoverChemed has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemed has recently increased by 6.13%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldChemed has a dividend yield of 0.37%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthChemed has been increasing its dividend for 16 years.Dividend CoverageThe dividend payout ratio of Chemed is 10.11%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Chemed will have a dividend payout ratio of 8.58% next year. This indicates that Chemed will be able to sustain or increase its dividend.Read more about Chemed's dividend. Sustainability and ESG4.9 / 5Environmental Score-0.33 Percentage of Shares Shorted2.13% of the float of Chemed has been sold short.Short Interest Ratio / Days to CoverChemed has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemed has recently increased by 6.13%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.59 News SentimentChemed has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Chemed this week, compared to 7 articles on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Chemed insiders have bought more of their company's stock than they have sold. Specifically, they have bought $75,328.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.32% of the stock of Chemed is held by insiders.Percentage Held by Institutions95.85% of the stock of Chemed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chemed's insider trading history. Receive CHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemed and its competitors with MarketBeat's FREE daily newsletter. Email Address CHE Stock News HeadlinesChemed (NYSE:CHE) Rating Lowered to "Hold" at StockNews.comMarch 1 at 1:43 AM | americanbankingnews.comDecoding Chemed Corp (CHE): A Strategic SWOT InsightMarch 1 at 12:48 AM | gurufocus.comI pulled a Joe Biden…Donald Trump wants to establish thousands of new AI mega-data centers across America. It’s all part of his $500 billion for American dominance over AI. For most, this is exciting. For me, it’s a sign that I was wrong. Since then, I've issued a number of other financial prophecies, many of which have come to pass precisely as I predicted. But today, I'm stepping forward with a new exposé that I believe could surpass anything I've ever done...March 1, 2025 | Porter & Company (Ad)Q4 2024 Chemed Corp Earnings CallFebruary 28 at 8:58 AM | finance.yahoo.comChemed Corp (CHE) Q4 2024 Earnings Call Highlights: Strong VITAS Growth Amid Roto-Rooter ChallengesFebruary 28 at 3:57 AM | finance.yahoo.comChemed Corporation (CHE) Q4 2024 Earnings Call TranscriptFebruary 27 at 3:10 PM | seekingalpha.comChemed’s Roto-Rooter Growth Offsets Vitas Challenges, Supporting Buy RatingFebruary 27 at 7:23 AM | tipranks.comChemed shares fall as Medicare cap concerns overshadow earnings beatFebruary 26 at 6:42 PM | uk.investing.comSee More Headlines CHE Stock Analysis - Frequently Asked Questions How have CHE shares performed this year? Chemed's stock was trading at $529.80 at the beginning of the year. Since then, CHE shares have increased by 13.3% and is now trading at $600.46. View the best growth stocks for 2025 here. How were Chemed's earnings last quarter? Chemed Co. (NYSE:CHE) released its quarterly earnings data on Tuesday, October, 29th. The company reported $5.64 EPS for the quarter, missing analysts' consensus estimates of $5.76 by $0.12. The business's revenue for the quarter was up 7.4% on a year-over-year basis. Who are Chemed's major shareholders? Chemed's top institutional shareholders include Vanguard Group Inc. (11.09%), Kayne Anderson Rudnick Investment Management LLC (3.87%), Kayne Anderson Rudnick Investment Management LLC (3.87%) and Neuberger Berman Group LLC (3.33%). Insiders that own company stock include Kevin J Mcnamara, Spencer S Lee, David Patrick Williams, Nicholas Michael Westfall, Andrea R Lindell, Donald E Saunders, Patrick P Grace, George J Walsh III, Michael D Witzeman and Brian C Judkins. View institutional ownership trends. How do I buy shares of Chemed? Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Chemed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chemed investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings10/29/2024Ex-Dividend for 12/6 Dividend11/18/2024Dividend Payable12/06/2024Ex-Dividend for 3/14 Dividend2/24/2025Today2/28/2025Dividend Payable3/14/2025Next Earnings (Estimated)4/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Home health care services Sub-IndustryHealth Care Services Current SymbolNYSE:CHE CIK19584 Webwww.chemed.com Phone(513) 762-6690Fax513-762-6590Employees15,087Year Founded1970Price Target and Rating Average Stock Price Target$633.00 High Stock Price Target$633.00 Low Stock Price Target$633.00 Potential Upside/Downside+5.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$19.79 Trailing P/E Ratio30.34 Forward P/E Ratio28.02 P/E Growth2.15Net Income$272.51 million Net Margins12.69% Pretax Margin16.61% Return on Equity27.86% Return on Assets19.12% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.81 Sales & Book Value Annual Sales$2.38 billion Price / Sales3.80 Cash Flow$26.81 per share Price / Cash Flow22.40 Book Value$73.55 per share Price / Book8.16Miscellaneous Outstanding Shares15,050,000Free Float14,550,000Market Cap$9.04 billion OptionableOptionable Beta0.48 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NYSE:CHE) was last updated on 3/1/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredDiscover the Key to a Resilient Investment PortfolioThese 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | SponsoredWall Street Legend: Crash coming in March—details hereStocks to Crash on March 16, 2026? Here's Compelling Reason Why Perhaps no one on or off Wall Street has be...Chaikin Analytics | SponsoredEx-CIA Officer Reveals Shocking 2025 Warning I don't know if Biden is evil and doing this on purpose or if he's senile and someone else is pulling the str...American Alternative | SponsoredTrump's Head-Spinning First Month Is Over, Here's What to Expect NextTrump's Head-Spinning First Month Is Over. Here's What to Expect Next for Social Security, Taxes and Stocks...Altimetry | Sponsored401K Savers Taking Advantage of “Tariffs” With Odd, 2-Word MoveYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWall St. legend shocks with “Next Nvidia” predictionWhen he recommended Microsoft at 38 cents… Google in 2005… and Nvidia before AI was mainstream, people called ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemed Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.